**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 59143

**Manuscript Type:** CASE REPORT

**Epstein-Barr virus-associated monomorphic post-transplant lymphoproliferative disorder after pediatric kidney transplantation: A case report**

Wang Z *et al*. EBV-associated monomorphic PTLD

Zhen Wang, Yang Xu, Jie Zhao, Ying-Xin Fu

**Zhen Wang, Yang Xu, Jie Zhao, Ying-Xin Fu,** Department of Kidney Transplantation, Tianjin First Central Hospital, Tianjin 300192, China

**Author contributions:** Wang Z and Fu YX contributed equally to this work; Fu YX performed the kidney transplant, guided the diagnosis and treatment of the patient, proposed the article and directed the writing of the article; Xu Y collected the clinical data; Wang Z analyzed the data and wrote the manuscript; Wang Z, Xu Y, and Zhao J participated in the diagnosis and treatment of the patient; All authors have read and approved the final manuscript.

**Corresponding author: Ying-Xin Fu, MD, PhD, Chief Doctor, Surgeon,** Department of Kidney Transplantation, Tianjin First Central Hospital, No. 24 Fukang Road, Nankai District, Tianjin 300192, China. fuyingxin@vip.163.com

**Received:** August 27, 2020

**Revised:** November 18, 2020

**Accepted:** November 29, 2020

**Published online:**

**Abstract**

BACKGROUND

Post-transplant lymphoproliferative disease (PTLD) is the most common malignant tumor that occurs after kidney transplantation in children, and is associated with Epstein-Barr virus (EBV).

CASE SUMMARY

We report a case of PTLD that occurred in a 17-year-old female patient at 5 mo post-transplant. The first symptom was abdominal pain accompanied by fever, nausea, and vomiting. EBV-associated monomorphic PTLD with multiple abdominal nodules was diagnosed by pathology, clinical manifestations, imaging results, and the presence of EB-DNA. After successful treatment with rituximab, the abdominal nodules in the spleen and liver disappeared.

CONCLUSION

Early pathological biopsy to confirm the diagnosis is critical to treatment and prognosis. Reducing immunosuppression and rituximab therapy are effective methods for treating PTLD, but need to be initiated as early as possible.

**Key Words:** Post-transplant lymphoproliferative disorder; Epstein-Barr virus; Kidney transplantation; Case report; Biopsy; Calcineurin inhibitors

Wang Z, Xu Y, Zhao J, Fu YX. Epstein-Barr virus-associated monomorphic post-transplant lymphoproliferative disorder after pediatric kidney transplantation: A case report. *World J Clin Cases* 2020; In press

**Core Tip:** Post-transplant lymphoproliferative disease (PTLD) is related to Epstein-Barr virus infection, but early onset and monomorphic PTLD in childhood kidney transplantation is rare. This case suggests that virological evaluation must be strengthened before and after kidney transplantation in children, and early pathological biopsy to confirm the diagnosis is critical to treatment and prognosis. Rituximab therapy combined with adjusting the immunosuppressive regimen are effective in pediatric kidney transplantation.

**INTRODUCTION**

Post-transplant lymphoproliferative disease (PTLD) is a rare but serious complication of renal transplantation in children, with an incidence of 1%-2%[1]. The incidence of PTLD is highest during the first year after kidney transplantation[2]. Significant risk factors for PTLD include positive Epstein-Barr virus (EBV) serology before renal transplantation and receiving strong immunosuppressive therapy after renal transplantation. Also, PTLD is more likely to occur in younger transplant recipients[3]. This case report describes a patient who developed PTLD after renal transplantation at our hospital, and reviews the relevant literature to provide a higher awareness of the disease.

**CASE PRESENTATION**

***Chief complaints***

A 17-year-old female was hospitalized with complaining of abdominal pain, a fever of 38 °C, nausea, and vomiting for 4 d on June 2019.

***History of present illness***

Four days before admission, the patient presented with lower abdomen pain accompanied by fever, nausea and vomiting, and went to the emergency room of our hospital. Computed tomography (CT) examination showed splenic mass, diffuse thickening of the small intestine wall in the left abdominal cavity, subcutaneous nodules in the right iliac fossae, and peritoneal effusion.

***History of past illness***

The recipient was diagnosed with allergic purpura in 2012. The disease progressed to end-stage renal disease and received dialysis in 2017. In January 2019, she underwent kidney transplantation with panel-reactive antibody(-), complement-dependent cytotoxicity(-). Balineximab was used for induction therapy. The kidney donor was a 22-year-old male who suffered from a head injury in a traffic accident. Laboratory results showed that the donor was EB virus antigen IgG-negative, EB virus shell antigen IgG-positive, EB virus shell antigen IgM-negative, cytomegalovirus (CMV) DNA < 400 copies/mL, BK virus DNA < 5000 copies/mL, procalcitonin < 0.05 ng/mL, IgG test < 60 pg/mL, and blood culture negative. A sputum culture was positive for *Corynebacterium* and a urine culture was positive for *Staphylococcus haemolyticus*. The graft showed good function during the perioperative period, under the immunosuppression of FK506 + mycophenolate mofetil (MMF) + Pred. However, by 18 d post-operation, the patient’s urine volume had progressively decreased to 150 mL/24 h, and creatinine increased from 91 μmol/L to 288 μmol/L. The patient did not respond to methylprednisolone, and her high flow rate through a renal artery anastomosis was monitored by contrast-enhanced ultrasound. The graft was rescued by successful balloon dilatation of the distal end of the renal artery, after which, the patient’s urine output returned to normal, and her creatinine (Cr) level returned to 108 μmol/L at 25 d post-operation.

***Personal and family history***

Unremarkable.

***Physical examination***

A physical examination revealed lower abdominal tenderness, rebound tenderness, and muscle tension.

***Laboratory examinations***

The patient’s laboratory results were as follows: white blood cells, 10.1 × 109/L; hemoglobin, 83 g/L; Cr, 98 μmol/L; troponin I, 0.01 ng/mL; procalcitonin, 10.2 ng/mL; C-reactive protein, 212 mg/L; neutrophil granulocytes%, 88.7%; LYBL%, 6.3%. A test for EB-DNA was positive at a level of 1.66 × 104 copies/mL.

***Imaging examinations***

CT scan showed splenomegaly, left abdomen intestinal thickening, and a right iliac subcutaneous nodule. Ultrasound showed multiple low echo groups in the spleen, and magnetic resonance imaging showed multiple spleen occupying nodules, multiple lymph nodes in the right iliac fossa and right inguinal region, and small intestinal wall thickening. Positron emission tomography/computed tomography (PET/CT) scans showed high levels of metabolism in the intestine, liver, spleen, left kidney, T1, L3, S1 vertebral bodies, and the iliac region, suggesting lymphoma (Figure 1).

**FINAL DIAGNOSIS**

Based on pathological biopsy and medical history, the patient was diagnosed as monomorphic PTLD with immunohistochemical positive: EBV-encoded small RNAs(+), cluster of differentiation 38 CD38(+), CD20(+), CD3(+), and Ki67 index of 45% (Figure 2).

**TREATMENT**

After confirmation of PTLD, we immediately changed the patient’s immunosuppressive therapy by stopping MMF and reducing dosage of FK506. Additionally, the patient received 375 mg/m2 rituximab targeted treatment once a week for eight rounds, and EB-DNA level was monitored once a week.

**OUTCOME AND FOLLOW-UP**

After two rounds of rituximab treatment, EB-DNA turned negative (< 400 copies/mL). After four rounds of rituximab, she had no fever, and PET/CT scan showed that the area of hypermetabolism in the spleen was significantly smaller than before. Furthermore, the hypermetabolic nodules in the liver had disappeared, the numbers of small intestinal lesions were significantly reduced, and signs of S1 vertebral hypermetabolism had disappeared. Subsequently, another four rounds of rituximab treatment were administered until CT showed the spleen’s multi-dimensional position as being unclear. The patient’s kidney function remained stable (creatinine, 56-74 μmol/L) throughout the course of treatment and the concentrations of FK506 was maintained at 5 ng/mL.

**DISCUSSION**

PTLD is a well-known malignant complication that can occur after pediatric renal transplantation. The cumulative incidence rate of PTLD in the first 10 years after transplantation is 1%-2% in adults and 3% in children; however, new evidence suggests that the incidence rate of PTLD may be decreasing over time[4,5]. Based on the time of occurrence, PTLD can be classified as either early-onset PTLD (occurring < 1 year after transplantation) or late-onset PTLD (occurring ≥ 1 year after transplantation). Here, we report a case of early-onset PTLD with multiple abdominal nodules, and also discuss the clinical characteristics, diagnosis, and treatment of PTLD, as well as the need for virological monitoring and making adjustments in immunosuppressive therapy. We also review the relevant literature.

It is well known that EBV infection increases the probability of developing PTLD after solid organ transplantation. A univariate analysis using the Cox proportional risk model showed that EBV was a risk factor for early onset PTLD[6]. Furthermore, the EBV positive rate among lymphoma tissue biopsies in the early-onset group was higher than that among biopsies in the late-onset group (88.9% *vs* 60%, respectively)[6]. A history of anti-rejection treatment was found to be a risk factor for late-onset PTLD, most likely because of decreased immunity of the recipients due to exposure to high doses of immunosuppressants[6]. The patient in this case was 17-years-old, EBV-DNA-positive, and had a history of methylprednisolone pulse therapy, all of which are risk factors for PTLD. Although co-infection with EBV and CMV is also a risk factor for PTLD, the patient described here was CMV negative, as determined by a blood serum test.

The patient displayed signs and symptoms that are typical for PTLD, including fever, sweating, and general discomfort, as well as of nausea and vomiting, because PTLD often involves the gastrointestinal tract, liver, and spleen. A physical examination revealed splenomegaly and right inguinal lymphadenopathy. According to the 2008 World Health Organization classification for lymphoid malignancies, this patient could be diagnosed as early onset (5 mo post-operation), monomorphic PTLD with a lymph node biopsy suggesting diffuse large B-cell lymphoma, which is the most frequent subtype in children. The patient’s good response to treatment with rituximab also suggested this diagnosis.

Currently, EBV virus seropositivity is an established risk factor for early-onset PTLD, and especially in children. The patient described in this report had EBV viremia (EBV-DNA: 1.66 × 104 copies/mL) when her clinical manifestations of PTLD occurred. We believe that being EBV positive might be an important factor in this patient.

Post-transplant monitoring of EBV in transplant recipients by serologic methods appears to be poorly predictive of PTLD and results in a considerable delay in detecting seroconversion. Serum quantitative EBV PCR seems to be required for early detection of primary EBV infection[7], and especially in EBV-seronegative children who receive an organ from an EBV-seropositive donor. Some studies suggest that an organ recipient’s EBV load should be monitored every 2 wk for the first 3 mo after surgery, and then every month for the second 3 mo, followed by every 3 mo for the last 6 mo[8]. However, there is no clear evidence that antiviral therapy helps to reduce a patient’s EBV load or prevent EBV infection[9].

Treatment options for PTLD vary based on the disease subtype, and may include rituximab monotherapy, and rituximab with concurrent or sequential chemoimmunotherapy, radiation or surgery. A nearly universal initial step is a reduction of immunosuppression. Balancing the mortality risk associated with PTLD with the risk of graft rejection in a setting of reduced immunosuppression is a major challenge for clinicians[10]. Most immunosuppression reduction algorithms include a reduction of the calcineurin inhibitor (CNI) dose (25% to 50% of baseline)[10]. A previous study found that a long-term reduction of immunosuppressive therapy administered post-chemotherapy did not appear to be associated with an increased risk for chronic graft dysfunction[11]. Many patients are switched to immunosuppressive regimens based on rapamycin inhibitors in a CNI-free regimen that includes prednisolone and/or MMF. However, a study found that a complete withdrawal of CNIs after developing PTLD was associated with poor long-term kidney graft function[10]. In children, there is evidence for a high rate of acute rejection after late CNI withdrawal[12], and CNI withdrawal also increases the risk for developing donor-specific antibodies[13]. In the case, we adopted the immunosuppressive therapy adjustment strategy of reducing CNI drugs and stopping MMF. The patient’s renal function remained normal throughout the course of treatment, but long-term monitoring was still required.

The treatment options for patients with monomorphic PTLD include rituximab with or without CHOP chemotherapy. Other studies have also demonstrated the effectiveness of RTX therapy. Michonneau *et al*[14] reported that the 5-year overall survival and disease-free survival rates for patients who received rituximab with or without chemotherapy were 69% and 80%, respectively. We used rituximab without chemotherapy in this patient and obtained a very good response. After two rounds of rituximab, the patient’s EB-DNA level turned negative (< 400 copies/mL), and after eight rounds of rituximab, the foci of the lesions in the spleen, liver, and intestinal wall became unclear, and there were no adverse reactions to the treatment. Although the use of rituximab has significantly improved the prognosis of patients with PTLD, with a treatment response rate of 52%, the long-term survival rate of patients with PTLD remains low, and the 1- and 3-year survival rates are 48% and 30%, respectively[15]. The patient described in this case report still requires long-term monitoring for signs of EB virus infection, as well as assessments of renal function and quality of life.

**CONCLUSION**

Based on this case and review of the relevant literature, we conclude that children who undergo renal transplantation remain at risk for developing PTLD. Early-onset PTLD is related to EBV infection and EBV-PCR should be performed on a regular basis after a kidney transplantation. Early pathological biopsy to confirm the diagnosis is critical to treatment and prognosis. Reducing immunosuppression and rituximab therapy are effective methods for treating PTLD, but need to be initiated as early as possible. Finally, there remains a need for further follow-up studies to determine PTLD patient survival times, graft function, and detect any adverse reactions to specific treatments.

**REFERENCES**

1 **Caillard S**, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, Morelon E, Moal V, Janbon B, Alamartine E, Pouteil Noble C, Morel D, Kamar N, Buchler M, Mamzer MF, Peraldi MN, Hiesse C, Renoult E, Toupance O, Rerolle JP, Delmas S, Lang P, Lebranchu Y, Heng AE, Rebibou JM, Mousson C, Glotz D, Rivalan J, Thierry A, Etienne I, Moal MC, Albano L, Subra JF, Ouali N, Westeel PF, Delahousse M, Genin R, Hurault de Ligny B, Moulin B. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. *J Clin Oncol* 2013; **31**: 1302-1309 [PMID: 23423742 DOI: 10.1200/JCO.2012.43.2344]

2 **Schober T**, Framke T, Kreipe H, Schulz TF, Großhennig A, Hussein K, Baumann U, Pape L, Schubert S, Wingen AM, Jack T, Koch A, Klein C, Maecker-Kolhoff B. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. *Transplantation* 2013; **95**: 240-246 [PMID: 23222898 DOI: 10.1097/TP.0b013e318277e344]

3 **Kanzelmeyer NK**, Maecker-Kolhoff B, Zierhut H, Lerch C, Verboom M, Haffner D, Pape L. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. *Transpl Int* 2018; **31**: 367-376 [PMID: 28906028 DOI: 10.1111/tri.13071]

4 **Quinlan SC**, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. *Am J Hematol* 2011; **86**: 206-209 [PMID: 21264909 DOI: 10.1002/ajh.21911]

5 **Caillard S**, Lamy FX, Quelen C, Dantal J, Lebranchu Y, Lang P, Velten M, Moulin B; French Transplant Centers. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. *Am J Transplant* 2012; **12**: 682-693 [PMID: 22226336 DOI: 10.1111/j.1600-6143.2011.03896.x]

6 **Gwon JG**, Kim YH, Han DJ. Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000. *Asian J Surg* 2019; **42**: 551-556 [PMID: 30327178 DOI: 10.1016/j.asjsur.2018.09.002]

7 **Hosseini-Moghaddam SM**, Alhomayeed B, Soliman N, Weir MA, House AA. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study. *Transpl Infect Dis* 2016; **18**: 423-430 [PMID: 27016725 DOI: 10.1111/tid.12533]

8 **Mohri T**, Ikura Y, Hirakoso A, Okamoto M, Hishizawa M, Takaori-Kondo A, Kato S, Nakamura S, Yoshimura K, Okabe H, Iwai Y. Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall. *Int J Hematol* 2018; **108**: 218-227 [PMID: 29380181 DOI: 10.1007/s12185-018-2410-x]

9 **Yamada M**, Nguyen C, Fadakar P, Ganoza A, Humar A, Shapiro R, Michaels MG, Green M. Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients. *Pediatr Transplant* 2018; **22**: e13147 [PMID: 29411474 DOI: 10.1111/petr.13147]

10 **Rabot N**, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. *Transpl Int* 2014; **27**: 956-965 [PMID: 24964147 DOI: 10.1111/tri.12375]

11 **Taylor E**, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB, Mollee P. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. *Nephrol Dial Transplant* 2015; **30**: 1774-1779 [PMID: 26188340 DOI: 10.1093/ndt/gfv260]

12 **Weintraub L**, Li L, Kambham N, Alexander S, Concepcion W, Miller K, Wong C, Salvatierra O, Sarwal M. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. *Pediatr Transplant* 2008; **12**: 541-549 [PMID: 18564305 DOI: 10.1111/j.1399-3046.2007.00847.x]

13 **OʼLeary JG**, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. *Transplantation* 2016; **100**: 39-53 [PMID: 26680372 DOI: 10.1097/TP.0000000000000869]

14 **Michonneau D**, Suarez F, Lambert J, Adam J, Brousse N, Canioni D, Anglicheau D, Martinez F, Snanoudj R, Legendre C, Hermine O, Mamzer-Bruneel MF. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. *Nephrol Dial Transplant* 2013; **28**: 471-478 [PMID: 23129824 DOI: 10.1093/ndt/gfs476]

15 **Cheung CY**, Ma MKM, Chau KF, Chak WL, Tang SCW. Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong. *Oncotarget* 2017; **8**: 96903-96912 [PMID: 29228580 DOI: 10.18632/oncotarget.18890]

**Footnotes**

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All study participants had no potential conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 27, 2020

**First decision:** November 3, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chiu KW **S-Editor:** Huang P **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**



**Figure 1 Positron emission tomography/computed tomography: High metabolism.** A: In the intestinal wall; B: In right iliac subcutaneous nodule; C: In the spleen and liver; D: In the S1 vertebral body.



**Figure 2 Right inguinal lymph node biopsy.**